Gitelman SyndromeCPPD and moreNCT06922370
The Osteoarticular Manifestations in Patients With Gitelman Syndrome
An observational study of Gitelman Syndrome and CPPD - Calcium Pyrophosphate Deposition Disease, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gitelman Syndrome, CPPD - Calcium Pyrophosphate Deposition Disease
- What is being tested?
- conventional radiograph or computed tomography
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 1 Nov 2021to 1 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients clinically and genetically confirmed with Gitelman Syndrome
Who may be able to join
- Patients confirmed with Gitelman Syndrome
Who cannot join
- Patients with other confounding situations such as Bartter Syndrome, hyperparathyroidism
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
the second affiliated hospital, Zhejiang University School of medicine
Hangzhou, Zhejiang, 310005
Ethics Committee of SAHZU, +86-057187783969, keyanlunli_zheer@163.com
About this study
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed.
Read the detailed description
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for calcium pyrophosphate deposition, and the clinical data and radiographic manifestations are collected and analyzed to investigate the osteoarticular features in patients with Gitelman Syndrome.
- Being tested
- conventional radiograph or computed tomography
- Medical subject headings
- Gitelman Syndrome, Chondrocalcinosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conventional radiograph or computed tomographyDiagnostic test
patients with gitelman syndrome evaluated with conventional radiograph or computed tomography
| Study group | Role | What they receive |
|---|---|---|
| Patients with Gitelman Syndrome | Patients with clinically and genetically confirmed Gitelman syndrome. Receives: Diagnostic Test: conventional radiograph or computed tomography |
What is being measured
The primary outcome is the main question the study is designed to answer.
The presence of chondrocalcinosis
The presence of chondrocalcinosis on conventional radiograph or computed tomography in patients with Gitelman Syndrome
Measured: From the enrollment to the performance of the CPPD screen
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2025
- Study start1 Nov 2021
- Primary completion1 Nov 2025 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gitelman SyndromeStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06922370
- Sponsor's protocol ID
- 2021-0670
- Acronym
- CPPD and more
- Status last verified
- Mar 2025
- First submitted
- 3 Apr 2025
- Last updated
- 10 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Osteoarticular Manifestations in Patients With Gitelman Syndrome
- ClinicalTrials.gov ID
- NCT06922370
- Acronym / sponsor ID
- CPPD and more / 2021-0670
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- 1 Nov 2021 (actual)
- Primary completion
- 1 Nov 2025 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 10 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed.
Detailed description
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for calcium pyrophosphate deposition, and the clinical data and radiographic manifestations are collected and analyzed to investigate the osteoarticular features in patients with Gitelman Syndrome.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Gitelman Syndrome | – | Diagnostic Test: conventional radiograph or computed tomographyPatients with clinically and genetically confirmed Gitelman syndrome. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients clinically and genetically confirmed with Gitelman Syndrome
Key inclusion criteria (1 listed)
- Patients confirmed with Gitelman Syndrome
Key exclusion criteria (1 listed)
- Patients with other confounding situations such as Bartter Syndrome, hyperparathyroidism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conventional radiograph or computed tomographypatients with gitelman syndrome evaluated with conventional radiograph or computed tomography | Diagnostic test | Patients with Gitelman Syndrome |
Primary outcome
The presence of chondrocalcinosis
Time frame: From the enrollment to the performance of the CPPD screen
The presence of chondrocalcinosis on conventional radiograph or computed tomography in patients with Gitelman Syndrome
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2025.
Related trials for Gitelman Syndrome
RecruitingObservational study
National Registry of Rare Kidney Diseases
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gitelman Syndrome and CPPD - Calcium Pyrophosphate Deposition Disease, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lijun Mou (+86-0571-89713751, moulj511@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The presence of chondrocalcinosis (time frame: From the enrollment to the performance of the CPPD screen). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2025.